Cover Story
Conversation with The Cancer LetterReal-world Evidence
The U.S. Supreme Court’s June 2022 decision to overturn Roe v. Wade has implications that reach far beyond access to reproductive health care services in the 41 states that ban or restrict access to abortion.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future - Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- Trump 2016: A look back at the 45th president’s impact on oncology